(MedPage Today) -- An investigational monoclonal antibody targeting interleukin 6 was effective in reducing the signs and symptoms of rheumatoid arthritis (RA), a phase II study found. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment